SCHEMBL10927112

SCHEMBL10927112

O=C1CCC(c2ccc(Cc3ncc[nH]3)cc2)=NN1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 10/20 0.52
▸ PDE3A Q14432 9/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ LMNA P02545 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ NPY1R P25929 1/20 0.49
▸ NPY2R P49146 1/20 0.49
▸ PDE4A P27815 2/20 0.48
▸ PDE4B Q07343 2/20 0.48
▸ PDE4C Q08493 2/20 0.48
▸ PDE4D Q08499 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ TAAR1 Q96RJ0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10927825 0.88 SMN1; SMN2 (0.49) PDE3BPDE3ASMN1; SMN2LMNAMAPT
SCHEMBL10730668 0.78 PDE3B (0.38) PDE3BPDE3ASMN1; SMN2LMNAMAPT
SCHEMBL10353452 0.76 SMN1; SMN2 (0.81) PDE3BPDE3ASMN1; SMN2LMNAMAPT
SCHEMBL10968242 0.76 SMN1; SMN2 (0.38) PDE3BPDE3ASMN1; SMN2LMNAMAPT
SCHEMBL7304104 0.75 SMN1; SMN2 (0.58) PDE3BPDE3ASMN1; SMN2LMNAMAPT
SCHEMBL13372830 0.74 TAAR1 (0.80) SMN1; SMN2LMNACYP2D6TSHRTAAR1
SCHEMBL7312349 0.74 SMN1; SMN2 (0.62) PDE3BPDE3ASMN1; SMN2LMNAMAPT
SCHEMBL7304108 0.73 SMN1; SMN2 (0.60) PDE3BPDE3ASMN1; SMN2LMNAMAPT
SCHEMBL11035016 0.72 SMN1; SMN2 (0.68) PDE3BPDE3ASMN1; SMN2LMNAMAPT
SCHEMBL7358963 0.72 SMN1; SMN2 (0.58) PDE3BPDE3ASMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4507298-A 6-{4-(ω-(1-imidazolyl)-alkyl-phenyl}-3-oxo-2,3,4,5-tetrahydro-pyridazines and acid addition salts thereof, and a process for the treatment of inflammatory, atherosclerotic and thromboembolic illnesses in humans A. NATTERMANN & CIE GMBH (DE) 1985-03-26 — — US claimed
EP-0071060-A2 6-(4-(Omega-(1-imidazolyl)-alkyl)-phenyl)-3-oxo-2,3,4,5-tetrahydro-pyridazines and their acid-addition salts, process for their preparation and pharmaceutical compounds containing them A. Nattermann & Cie. GmbH (DE) 1983-02-09 — — EP claimed
EP-0071060-B1 6-(4-(OMEGA-(1-IMIDAZOLYL)-ALKYL)-PHENYL)-3-OXO-2,3,4,5-TETRAHYDRO-PYRIDAZINES AND THEIR ACID-ADDITION SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1986-09-10 — — EP disclosed
US-4507298-A 6-{4-(ω-(1-imidazolyl)-alkyl-phenyl}-3-oxo-2,3,4,5-tetrahydro-pyridazines and acid addition salts thereof, and a process for the treatment of inflammatory, atherosclerotic and thromboembolic illnesses in humans A. NATTERMANN & CIE GMBH (DE) 1985-03-26 — — US disclosed
EP-0071060-A2 6-(4-(Omega-(1-imidazolyl)-alkyl)-phenyl)-3-oxo-2,3,4,5-tetrahydro-pyridazines and their acid-addition salts, process for their preparation and pharmaceutical compounds containing them A. Nattermann & Cie. GmbH (DE) 1983-02-09 — — EP disclosed
Send feedback